CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 121 enrolled
Drug / intervention
Transdermal nicotine patch +1 moredrug
Likely dose
Transdermal nicotine patch 7mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01315002
NCT01315002N/ACompleted
CompareCT.gov

Nicotine Effects on Endophenotypes of Schizophrenia

University Hospital, Bonn·interventional·Posted Mar 15, 2011·Updated Jan 16, 2015

In Brief

A clinical study evaluating Transdermal nicotine patch and Placebo patch for Schizophrenia. Completed, enrolled 121 participants.

Detailed Summary

The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected first-degree relatives of schizophrenia patients and healthy controls receive transdermal nicotine in a double-blind, placebo-controlled, crossover study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
Countries--
CollaboratorsGerman Research Foundation

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 15, 2011
Enrollment StartJul 1, 2008
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.3 years ago

Interventions

Transdermal nicotine patchdrug

7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)

Placebo patchdrug

Placebo patch